ArticleMedicine2018
Peroral endoscopic cardial constriction in gastroesophageal reflux disease.
Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Pooled it
- Transoral Endoscopic Clip Band Ligation Anti-reflux Therapy (C-BLART) for Gastroesophageal Reflux Disease: A Retrospective Analysis of Efficacy and Safety in 37 Patients.Digestive diseases and sciences · 2026Article
- Peroral Endoscopic Cardial Constriction with Band Ligation for Gastroesophageal Reflux Disease: A Prospective Pilot Study.Endoscopy international open · 2026Article
- Efficacy and safety of endoscopic cardia constriction ligation with a single-use endoscope versus a reusable endoscope for refractory gastroesophageal reflux disease: protocol for a multicenter randomized controlled trial.Frontiers in medicine · 2026Article
- Application status of endoscopic anti-reflux mucosal interventions in the treatment of gastroesophageal reflux disease.World journal of gastrointestinal surgery · 2025Review
- Anti-Reflux Mucosectomy: Our Experience & Thoughts For The Future.Current gastroenterology reports · 2025Review
- Efficacy of laparoscopic cardiectomy combined with side overlap anastomosis for the treatment of terminal achalasia.Scientific reports · 2025Article
- Endoscopic Advances in the Diagnosis and Management of Gastroesophageal Reflux Disease.Medicina (Kaunas, Lithuania) · 2024Review
- Anti-reflux mucosectomy (ARMS) for refractory gastroesophageal reflux disease.European journal of medical research · 2024Review
- Role of endoscopy in gastroesophageal reflux disease.Clinical endoscopy · 2023Review
- Minimally invasive endoscopic therapies for gastro-oesophageal reflux disease.Frontline gastroenterology · 2023Article
- Review
- Endoscopic anti-reflux therapy for gastroesophageal reflux disease.World journal of gastroenterology · 2021Review
- Article
- Advanced Endoscopic Imaging and Interventions in GERD: An Update and Future Directions.Frontiers in medicine · 2021Review
- Diagnosis and Etiological Analysis of Gastroesophageal Reflux Disease by Gastric Filling Ultrasound and GerdQ Scale.Journal of healthcare engineering · 2021Article
- Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.Current gastroenterology reports · 2020Review
- Update on Endoscopic Approaches for the Management of Gastroesophageal Reflux Disease.Gastroenterology & hepatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal reflux disease (GERD) is a major digestive health problem with a high and increasing incidence worldwide. Peroral endoscopic cardial constriction (PECC) was developed by our group to provide a less invasive treatment for GERD.In this preliminary follow-up study, 16 patients were enrolled and 13 patients with GERD were targeted for analysis according to the Los Angeles classification of reflux esophagitis. The GERD health-related quality of life (GERD-HRQL) scale and esophageal pH monitoring were applied to assess clinical efficiency at 3 and 6 months after PECC treatment, respectively.All GERD patients successively received PECC, and no severe treatment-related complication was reported. Before PECC treatment, the GERD-HRQL scale was 19.92 ± 7.89. At 3 and 6 months after treatment, the GERD-HRQL scale was 4.46 ± 4.31 and 5.69 ± 5.07, respectively. DeMeester score was 125.50 ± 89.64 before PECC treatment, and 16.97 ± 12.76 and 20.32 ± 15.22 at 3 and 6 months after PECC treatment. Furthermore, the fraction time of a pH below 4 significantly decreased at 3 and 6 months after PECC treatment. Fraction time at pH <4 was 35.55 ± 26.20 before PECC treatment and 7.96 ± 13.03 and 4.72 ± 3.78 at 3 and 6 months after PECC treatment, respectively. These results suggest that PECC treatment could significantly reduce the GERD-HRQL scale and DeMeester score (P < .01).PECC is a feasible, safe, and effective method to treatment GERD through narrowing the diameter of the cardia and preventing the reflux of stomach contents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.